318
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      scite_
       
      • Record: found
      • Abstract: found
      • Conference Proceedings: found
      Is Open Access

      PHARMACOMES: Cause-and-Effect Models linking Drugs, Targets and Disease Mechanisms

      Published
      proceedings-article
      1 ,
      ScienceOpen
      RExPO22
      2-3 September, 2022
      Pathophysiology, Pharmacome, Drug repurposing, Cause-and-Effect models, Alzheimer, Parkinsonism, COVID-19
      Bookmark

            Abstract

            Cause-and-Effect models are knowledge assemblies representing essential causal and correlative relationships in a pre-defined disease context. Unlike “pathways”, Cause-and-Effect models can span across scales and readily integrate clinical readouts and endpoints. In my talk, I will guide through some of our work on generating Cause-and-Effect models in the field of neurodegenerative diseases (Alzheimer; Parkinsonism) and will demonstrate, how we generate those using advanced, AI-based “text-2-graph” workflows.

            The enrichment of Cause-and-Effect models with drug-target information allows us to generate “disease-specific PHARMACOMES”. PHARMACOMES link drug-target information to specific pathophysiology mechanisms and are ideally suited for rational approaches towards modulation of pathophysiology mechanisms. Examples for productive usage of this novel approach in drug repurposing experiments will cover the COVID-19 PHARMACOME and the Human Brain PHARMACOME

            Content

            Author and article information

            Conference
            ScienceOpen
            25 August 2022
            Affiliations
            [1 ] Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing (SCAI), Sankt Augustin, Germany
            Article
            10.14293/S2199-rexpo22006.v1
            9a64ace8-d4af-4907-a63f-705b79fd3d25
            The Author

            Published under Creative Commons Attribution 4.0 International ( CC BY 4.0). Users are allowed to share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material for any purpose, even commercially), as long as the authors and the publisher are explicitly identified and properly acknowledged as the original source.

            RExPO22
            Maastricht, Netherlands
            2-3 September, 2022
            History

            Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
            Pathophysiology,Parkinsonism,Alzheimer,COVID-19,Cause-and-Effect models,Drug repurposing,Pharmacome

            Comments

            Comment on this article